Lupin signs promotional agreement with Exeltis to promote SOLOSEC; Stock up 1.5%

28 Jan 2022 , 10:40 AM

Lupin Limited informed the exchanges Thursday that Lupin Pharmaceuticals Inc. and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients. SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).

At around 10.44 am, Lupin Ltd was trading at Rs901.65 per piece up by Rs13.55 or 1.53% from its previous closing of Rs888.10 per piece on the BSE.

“This partnership will expand the reach of SOLOSEC, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis,” said Vinita Gupta, Chief Executive Officer of Lupin.

“We are extremely excited to partner with Exeltis. Our team is thrilled to embark on this partnership. The addition of Solosec fits precisely within our current portfolio of products, enhancing our commercial strategy, and offering numerous solutions to our customers and their patients,” Salustiano Perez, Chief Executive Officer of Exeltis added.